EUVIMEDEUVIMED entdecken
Crossref

The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients

Yu-Lien Tsai, Meng-Hsuan Chung, Niang-Cheng Lin, Cheng-Yen Chen, Yao-Ping Lin, Ming-Tsun Tsai, Hsin-Lin Tsai, Yee-An Chen, Shuo-Ming Ou, Chi-Jen Chu, Tsai-Hung Wu, Chang-Youh Tsai

American Journal of Nephrology · 2024

DOI: 10.1159/000538231 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, 2024. Verfasst von Yu-Lien Tsai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Nephrology, En Chu Kong Hospital, New Taipei City, Taiwan. Hauptthemen laut MEDLINE: Kidney Transplantation, Virus Activation, Hepatitis B Surface Antigens, Graft Survival. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Hepatitis B virus (HBV) infection is prevalent in Asia including Taiwan. We retrospectively evaluated the risk of HBV reactivation and clinical outcomes in HBV+ and HBV– kidney transplant recipients.

Methods

Patients who underwent kidney transplantation between January 2004 and December 2021 were reviewed. The outcomes of interest included risks of HBV reactivation and patient/graft survival.

Results

We identified 337 patients (47.5 ± 12 years) in our final cohort. Fifty-two (15.4%) had hepatitis B surface antigen (HBsAg) positive at the time of transplantation. Seventeen developed viral reactivations, with 41.2% of them accompanied by active hepatitis. The graft survival, acute rejection rate, and cancer development after kidney transplantation did not differ in terms of HBsAg status. The Cox multivariate analysis indicated the HBV reactivation risk was increased by a lack of pretransplant anti-HBV medication (hazard ratio [HR], 5.95; 95% confidence interval [CI], 1.31–27.02; p = 0.021) or an absence of lifelong antiviral therapy (HR: 3.14; 95% CI: 1.01–9.74; p = 0.047).

Conclusion

Individuals, independent of HBsAg status, had similar prognosis in terms of patient and graft survival, acute rejection rate, and cancer development. The absence of either pretransplant anti-HBV medication or lifelong antiviral therapy was significantly associated with an increased risk of HBV reactivation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationVirus ActivationHepatitis B Surface AntigensGraft SurvivalHepatitis B virusGraft RejectionHumansMaleMiddle AgedFemaleRetrospective StudiesRisk FactorsAdultHepatitis BAntiviral AgentsTaiwan

Stichwörter der Autor:innen

Antiviral therapyHepatitis B virusKidney transplantReactivationRisk factor

Substanzen

Hepatitis B Surface AntigensAntiviral Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Nephrology, En Chu Kong Hospital, New Taipei City, Taiwan.
  • Division of Nephrology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • School of Medicine, College of Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.
  • Division of Transplantation Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Division of Trauma, Department of Emergency Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei, Taiwan.

Zitieren

APA

Tsai, Y. L., Chung, M. H., Lin, N. C., Chen, C. Y., Lin, Y. P., Tsai, M. T., Tsai, H. L., Chen, Y. A., Ou, S. M., Chu, C. J., Wu, T. H., & Tsai, C. Y. (2024). The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. American Journal of Nephrology. https://doi.org/10.1159/000538231

Vancouver

Tsai YL, Chung MH, Lin NC, Chen CY, Lin YP, Tsai MT, et al. The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients. American Journal of Nephrology. 2024. doi:10.1159/000538231

BibTeX
@article{Tsai2024,
  author = {Tsai, Yu-Lien and Chung, Meng-Hsuan and Lin, Niang-Cheng and Chen, Cheng-Yen and Lin, Yao-Ping and Tsai, Ming-Tsun and Tsai, Hsin-Lin and Chen, Yee-An and Ou, Shuo-Ming and Chu, Chi-Jen and Wu, Tsai-Hung and Tsai, Chang-Youh},
  title = {The Risk Factors and Clinical Outcomes in Hepatitis B Seropositive and Seronegative Renal Transplant Patients},
  journal = {American Journal of Nephrology},
  year = {2024},
  doi = {10.1159/000538231}
}
Kostenlos starten →